Study Group: Nevanac (Nepafenac Ophthalmic Solutions) Prescribers: Ophthalmologists (US)
Council Members in this Study Group: 13
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Barry SchechterDirector of Corneal and External Diseases
FLORIDA EYE MICROSURGICAL INSTITUTE INC
Barry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal,...
- Andrew Dahl
President
Ophthalmology ConsultantsAndrew Dahl, MD, FACS, FAAO, is the President of Ophthalmology Consultants in New York. He was also Principal Investigator for Hudson Valley Eye Research Foundation and has conducted numerous clinical trials. Dr. Dahl is a board-certified Ophthalmologist/Ophthalmic...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Lumigan X EU Committee Recomendation
October 27, 2009
Analysis by: Andrew Dahl, President ,EU committee backs marketing approval of Lumigan | www.pharmabiz.com
The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. Lumigan X offers Allergan a new formulation to compete against generic versions of its glaucoma drug Lumigan after patent protection for Lumigan expires shortly.There will be very limited demand for Lumigan-X.
-
Bausch makes foray into presbyopic arena
January 29, 2008
Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
-
U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo
November 8, 2007
Analysis by: Andrew Dahl, President ,Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent rights on the combination whose two components individually have multiple generic competitors.
-
Interesting Approach to the Lucrative Dry Eye Market
October 16, 2007
Analysis by: Andrew Dahl, President ,Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 | www.pipelinereview.com
Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small clinical trial produced promising results, the FDA will require both subjective (patients feeling better) and objective (decreased conjunctival and corneal staining) statistical advantage over placebo in two phase III trials prior to approval of the eye drop drug.
-
Restriction on Avastin distribution will add to Genenetech's bottom line.
October 15, 2007
Analysis by: Andrew Dahl, President ,Maker Seeks to Restrict Cancer Drug Used on Eye | www.nytimes.com
Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label. Although this amount of sales places Lucentis well within the blockbuster category, Genenetech realizes that, were it not for the off-label use of its own drug Avastin for treatment of the same conditions, revenues would have been $1.2 billion for that same period. Vials of Avastin containing either 100 mg. or 400 mg. are currently being split into 1 mg doses by compounding pharmacies, dropping the price per dose to the $50 range as opposed to the $2000 per dose price for Lucentis.
Members in this Study Group include these company types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- President
- Owner
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
April 19, 2006 | New York
GLGi: Ophthalmology Grand RoundsGLG Webcasts & Teleconferences
Leading Experts in Nevanac (Nepafenac Ophthalmic Solutions) Prescribers: Ophthalmologists (US) have not participated in any GLG webcasts.